Strategies to eliminate HBV infection

Future Virology

Volumn 9, Issue 6, 2014, Pages 565-585

  Kapoor, Rama ^a,b   Kottilil, Shyam ^b  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

covalently closed circular DNA; cure; elimination; eradication; HBV; host; IL 21; IL 7; immunity; PD 1; PD L1; receptor; RNAi; seroconvesrion; therapeutic vaccination; Toll like receptor; treatment; vaccines; viral entry; virus

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; CIRCULAR DNA; COMPLEMENTARY DNA; COVALENTLY CLOSED CIRCULAR DNA; DNA VACCINE; ENTECAVIR; GS 4774; GS 9620; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HOST FACTOR; INTERLEUKIN 21; INTERLEUKIN 7; LAMIVUDINE; PEGINTERFERON ALPHA; PROGRAMMED DEATH 1 LIGAND 1; RECOMBINANT INTERLEUKIN 21; RECOMBINANT INTERLEUKIN 7; TELBIVUDINE; TENOFOVIR; TG 1050; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADENOVIRUS; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DRUG TARGETING; ENCAPSULATION; EPIGENETICS; GENE SILENCING; GENETICS; GENOTYPE; HEPATITIS B; HUMAN; IMMUNOGENICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; SEROCONVERSION; SINGLE DRUG DOSE; VACCINATION; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 84905258651     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.14.36     Document Type: Review

References (185)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specifc HBsAg seroprevalence and endemicity. Vaccine 30(12), 2212-2219 (2012).
2. Buster EH, Flink HJ, Cakaloglu Y et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 135(2), 459-467 (2008).
3. van Zonneveld M, Honkoop P, Hansen BE et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39(3), 804-810 (2004).
4. Wong VW, Wong GL, Yan KK et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51(6), 1945-1953 (2010).
5. Buster EH, Hansen BE, Lau GK et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 137(6), 2002-2009 (2009).
6. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365(9454), 123-129 (2005).
7. Liaw YF, Jia JD, Chan HL et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 54(5), 1591-1599 (2011).
8. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354 (10), 1001-1010 (2006).
9. Chang TT, Liaw YF, Wu SS et al. Long-term entecavir therapy results in the reversal of fbrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52(3), 886-893 (2010).
10. Marcellin P, Gane E, Buti M et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381(9865), 468-475 (2013).
11. Heathcote EJ, Marcellin P, Buti M et al. Three-year effcacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140(1), 132-143 (2011).
12. Gish RG, Chang TT, Lai CL et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J. Viral Hepat. 17(1), 16-22 (2010).
13. Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130(3), 678-686 (2006).
14. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1), 65-73 (2006).
15. Lee MH, Yang HI, Liu J et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profles. Hepatology 58(2), 546-554 (2013).
16. Clements CJ, Coghlan B, Creati M, Locarnini S, Tedder RS, Torresi J. Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization? Bull. World Health Organ. 88(1), 66-73 (2010).
17. Devi U, Locarnini S. Hepatitis B antivirals and resistance. Curr. Opin. Virol. 3(5), 495-500 (2013).
18. Locarnini SA, Yuen L. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antiviral Ther. 15(3 Pt B), 451-461 (2010)
19. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 57(1), 167-185 (2012).
20. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 57(1), 84-90 (2008).
21. Moucari R, Marcellin P. [HBsAg seroclearance: prognostic value for the response to treatment and the long-term outcome]. Gastroenterol. Clin Biol. 34(Suppl. 2), S119-S125 (2010).
22. Ruan P, Xu SY, Zhou BP, Huang J, Gong ZJ. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study J. Int. Med. Res. 41(5), 1732-1739 (2013).
23. Chotiyaputta W, Lok AS. Endpoints of hepatitis B treatment. J. Viral Hepat. 17(10), 675-684 (2010).
24. Chan HL, Wong VW, Tse AM et al. Serum hepatitis B surface antigen quantitation can refect hepatitis B virus in the liver and predict treatment response. Clin. Gastroenterol. Hepatol. 5(12), 1462-1468 (2007).
25. Thompson AJ, Nguyen T, Iser D et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase infuences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51(6), 1933-1944 (2010).
26. Wieland SF, Chisari FV Stealth and cunning: hepatitis B and hepatitis C viruses. J. Virol. 79(15), 9369-9380 (2005).
27. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc. Natl Acad. Sci. USA 93(9), 4398-4402 (1996).
28. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 31(5), 1037-1044 (2000).
29. Sonneveld MJ, Rijckborst V, Zeuzem S et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology 56(1), 67-75 (2012).
30. Takahashi K, Aoyama K, Ohno N et al. The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical signifcance and an easy method for detection. J. Gen. Virol. 76(Pt 12), 3159-3164 (1995).
31. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identifed in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J. Clin. Invest. 98(10), 2268-2276 (1996).
32. Fang ZL, Yang J, Ge X et al. Core promoter mutations (A(1762)T and G(1764)A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China. J. Med. Virol. 68(1), 33-40 (2002).
33. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124(2), 327-334 (2003).
34. Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 40(4), 790-792 (2004).
35. Ito K, Yotsuyanagi H, Yatsuhashi H et al. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology 59(1), 89-97 (2014).
36. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J. Gastrenterol. Hepatol. 26(Suppl. 1), 123-130 (2011).
37. Seeger C, Mason WS. Hepatitis B virus biolog y. Microbiol. Mol. Biol. Rev. 64(1), 51-68 (2000).
38. Sung JJ, Wong ML, Bowden S et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 128(7), 1890-1897 (2005).
39. Werle-Lapostolle B, Bowden S, Locarnini S et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126(7), 1750-1758 (2004).
40. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J. Hepatol. 42(3), 302-308 (2005).
41. Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplifed by an intracellular pathway. Virology 175(1), 255-261 (1990).
42. Thursz MR, Kwiatkowski D, Allsopp CE, Greenwood BM, Thomas HC, Hill AV. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N. Engl. J. Med. 332(16), 1065-1069 (1995)
43. An P, Winkler C, Guan L, O'Brien SJ, Zeng Z, Consortium HBVS. A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance in Han Chinese. J. Infect. Dis. 203(7), 943-947 (2011).
44. Hu L, Zhai X, Liu J et al. Genetic variants in human leukocyte antigen/DP-DQ infuence both hepatitis B virus clearance and hepatocellular carcinoma development. Hepatology 55(5), 1426-1431 (2012).
45. Mbarek H, Ochi H, Urabe Y et al. A genome-wide association study of chronic hepatitis B identifed novel risk locus in a Japanese population. Hum. Mol. Genet. 20(19), 3884-3892 (2011).
46. Nishida N, Sawai H, Matsuura K et al. Genome-wide association study confrming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS ONE 7(6), e39175 (2012).
47. Wang L, Wu XP, Zhang W et al. Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese: two independent case-control studies. PLoS ONE 6(3), e17608 (2011).
48. Kamatani Y, Wattanapokayakit S, Ochi H et al. A genome-wide association study identifes variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat. Genet. 41(5), 591-595 (2009).
49. Almarri A, Batchelor JR. HLA and hepatitis B infection. Lancet 344(8931), 1194-1195 (1994).
50. Jiang YG, Wang YM, Liu TH, Liu J. Association between HLA class II gene and susceptibility or resistance to chronic hepatitis B. World J. Gastroenterol. 9(10), 2221-2225 (2003).
51. Milich DR, Leroux-Roels GG. Immunogenetics of the response to HBsAg vaccination. Autoimmun. Rev. 2(5), 248-257 (2003).
52. Ahn SH, Han KH, Park JY et al. Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology 31(6), 1371-1373 (2000).
53. Meng XQ, Chen HG, Ma YL, Liu KZ. Infuence of HLA class II molecules on the outcome of hepatitis B virus infection in population of Zhejiang Province in China. Hepatobiliary Pancreat. Dis. Int. 2(2), 230-233 (2003).
54. Ramezani A, Hasanjani Roshan MR, Kalantar E et al. Association of human leukocyte antigen polymorphism with outcomes of hepatitis B virus infection. J. Gastrenterol. Hepatol. 23(11), 1716-1721 (2008).
55. Thio CL, Carrington M, Marti D et al. Class II HLA alleles and hepatitis B virus persistence in African Americans. J. Infect. Dis. 179(4), 1004-1006 (1999).
56. Zhang SY, Gu HX, Li D et al. Association of human leukocyte antigen polymorphism with hepatitis B virus infection and genotypes. Jpn. J. Infect. Dis. 59(6), 353-357 (2006).
57. Thursz M, Yee L, Khakoo S. Understanding the host genetics of chronic hepatitis B and C. Semin. Liver Dis. 31(2), 115-127 (2011).
58. Frodsham AJ, Zhang L, Dumpis U et al. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc. Natl Acad. Sci. USA 103(24), 9148-9153 (2006).
59. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgrad. Med. J. 89(1051), 294-304 (2013).
60. Yan H, Zhong G, Xu G et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1, e00049 (2012).
61. Gripon P, Cannie I, Urban S. Effcient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J. Virol. 79(3), 1613-1622 (2005).
62. Schulze A, Schieck A, Ni Y, Mier W, Urban S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J. Virol. 84(4), 1989-2000 (2010).
63. Petersen J, Dandri M, Mier W et al Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol. 26(3), 335-341 (2008).
64. Volz T, Allweiss L, Ben MM et al. The entry inhibitor Myrcludex-B effciently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J. Hepatol. 58(5), 861-867 (2013).
65. Deres K, Schroder CH, Paessens A et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299(5608), 893-896 (2003).
66. Stray SJ, Bourne CR, Punna S, Lewis WG, Finn MG, Zlotnick A. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc. Natl Acad. Sci. USA 102(23), 8138-8143 (2005).
67. Stray SJ, Zlotnick A. BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J. Mol. Recognit. 19(6), 542-548 (2006).
68. Wu GY, Zheng XJ, Yin CC et al. Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly. J. Chemother. 20(4), 458-467 (2008).
69. Zhu X, Zhao G, Zhou X et al. 2, 4-Diaryl-4, 6, 7, 8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly. Bioorg. Med. Chem. Lett. 20(1), 299-301 (2010).
70. Billioud G, Pichoud C, Puerstinger G, Neyts J, Zoulim F. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Res. 92(2), 271-276 (2011).
71. Delaney WEt, Edwards R, Colledge D et al. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrobial Agents Chemother. 46(9), 3057-3060 (2002).
72. Feld JJ, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res. 76(2), 168-177 (2007).
73. Katen SP, Chirapu SR, Finn MG, Zlotnick A. Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem. Biol. 5(12), 1125-1136 (2010).
74. Katen SP, Tan Z, Chirapu SR, Finn MG, Zlotnick A. Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure. Structure 21(8), 1406-1416 (2013).
75. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med. 350(11), 1118-1129 (2004).
76. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5(3), 215-229 (2005).
77. Dunn C, Peppa D, Khanna P et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137(4), 1289-1300 (2009).
78. Dougherty AM, Guo H, Westby G et al. A substituted tetrahydro-tetrazolo-pyrimidine is a specifc and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrobial Agents Chemother. 51(12), 4427-4437 (2007).
79. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-s sequence. J. Virol. 52(2), 396-402 (1984).
80. Yu W, Goddard C, Clearfeld E et al. Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. J. Med. Chem. 54(16), 5660-5670 (2011).
81. Op den Brouw ML, Binda RS, Geijtenbeek TB, Janssen HL, Woltman AM. The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells. Virology 393(1), 84-90 (2009).
82. Xu Y, Hu Y, Shi B et al. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol. Immunol. 46(13), 2640-2646 (2009).
83. Korba BE, Montero AB, Farrar K et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 77(1), 56-63 (2008).
84. Prange R. Host factors involved in hepatitis B virus maturation, assembly, and egress. Med. Microbiol. Immunol. 201(4), 449-461 (2012).
85. Durantel D, Alotte C, Zoulim F. Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr. Opin. Invest. Drugs 8(2), 125-129 (2007).
86. Lazar C, Durantel D, Macovei A et al. Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. Antiviral Res. 76(1), 30-37 (2007).
87. Mehta A, Carrouee S, Conyers B et al. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology 33(6), 1488-1495 (2001).
88. Mehta A, Zitzmann N, Rudd PM, Block TM, Dwek RA. Alpha-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Lett. 430(1-2), 17-22 (1998).
89. Simsek E, Lu X, Ouzounov S, Block TM, Mehta AS. alpha-Glucosidase inhibitors have a prolonged antiviral effect against hepatitis B virus through the sustained inhibition of the large and middle envelope glycoproteins. Antiviral Chem. Chemother. 17(5), 259-267 (2006).
90. Carroll D. Genome engineering with zinc-fnger nucleases. Genetics 188(4), 773-782 (2011).
91. Zimmerman KA, Fischer KP, Joyce MA, Tyrrell DL. Zinc fnger proteins designed to specifcally target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J. Virol. 82(16), 8013-8021 (2008).
92. Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP. Zinc-fnger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol. Ther. 18(5), 947-954 (2010).
93. Handel EM, Gellhaus K, Khan K et al. Versatile and effcient genome editing in human cells by combining zinc-fnger nucleases with adeno-associated viral vectors. Hum Gene Ther. 23(3), 321-329 (2012).
94. Cai D, Mills C, Yu W et al. Identifcation of disubstituted sulfonamide compounds as specifc inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrobial Agents Chemother. 56(8), 4277-4288 (2012).
95. Lucifora J, Xia Y, Reisinger F et al. Specifc and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343 (6176), 1221-1228 (2014).
96. Belloni L, Allweiss L, Guerrieri F et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J. Clin. Invest. 122(2), 529-537 (2012).
97. Zu Putlitz J, Wieland S, Blum HE, Wands JR. Antisense RNA complementary to hepatitis B virus specifcally inhibits viral replication. Gastroenterology 115(3), 702-713 (1998).
98. Welch PJ, Tritz R, Yei S, Barber J, Yu M. Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther. 4(7), 736-743 (1997).
99. Nash KL, Alexander GJ, Lever AM. Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes. J. Viral Hepat. 12(4), 346-356 (2005).
100. Hannon GJ. RNA interference. Nature 418(6894), 244-251 (2002).
101. Chen Y, Cheng G, Mahato RI. RNAi for treating hepatitis B viral infection. Pharm. Res. 25(1), 72-86 (2008).
102. Klein C, Bock CT, Wedemeyer H et al. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 125(1), 9-18 (2003).
103. McCaffrey A P, Nakai H, Pandey K et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. 21(6), 639-644 (2003).
104. Morrissey DV, Lockridge JA, Shaw L et al. Potent and persistent in vivo anti-HBV activity of chemically modifed siRNAs. Nat. Biotechnol. 23(8), 1002-1007 (2005).
105. Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 37(4), 764-770 (2003).
106. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006).
107. Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS ONE 6(1), e15324 (2011).
108. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl Acad. Sci. USA 101(17), 6669-6674 (2004).
109. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 5(12), 1219-1226 (2004).
110. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8(8), 594-606 (2008).
111. An BY, Xie Q, Lin LY et al. [Expression of Toll-like receptor 3 on peripheral blood dendritic cells in HBeAg positive patients with chronic hepatitis B]. Zhonghua gan zang bing za zhi 15(10) 729-733 (2007).
112. Chen Z, Cheng Y, Xu Y et al. Expression profles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin. Immunol. 128(3), 400-408 (2008).
113. Hirsch I, Caux C, Hasan U, Bendriss-Vermare N, Olive D. Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol. 31(10), 391-397 (2010).
114. Momeni M, Zainodini N, Bidaki R et al. Decreased expression of toll like receptor signaling molecules in chronic HBV infected patients. Hum. Immunol. 75(1), 15-19 (2014).
115. Isogawa M, Robek MD, Furuichi Y, Chisari F V. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 79(11), 7269-7272 (2005).
116. Wieland SF, Guidotti LG, Chisari F V. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J. Virol. 74(9), 4165-4173 (2000).
117. Zhang X, Kraft A, Broering R, Schlaak JF, Dittmer U, Lu M. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert. Opin. Drug Discov. 7(7), 597-611 (2012).
118. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 130(6), 1886-1900 (2006).
119. Visvanathan K, Skinner NA, Thompson AJ et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 45(1), 102-110 (2007).
120. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pat hway. J. Hepatol. 55(4), 762-769 (2011).
121. Wang H, Ryu WS. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog. 6(7), e1000986 (2010).
122. Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z. Hepatitis B virus polymerase inhibits RIG-I-and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J. Gen. Virol. 91(Pt 8), 2080-2090 (2010).
123. Wu J, Meng Z, Jiang M et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49 (4), 1132-1140 (2009).
124. Lanford RE, Guerra B, Chavez D et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144 (7), 1508-1517, 1517 e1501-1510 (2013).
125. Lopatin U, Wolfgang G, Tumas D et al. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist. Antiviral Ther. 18 (3), 409-418 (2013)
126. A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection. http://clinicaltrials.gov/show/NCT01590654
127. A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B. http://clinicaltrials.gov/show/NCT01590641
128. Nanjappa SG, Kim EH, Suresh M. Immunotherapeutic effects of IL-7 during a chronic viral infection in mice. Blood 117(19), 5123-5132 (2011).
129. Pellegrini M, Calzascia T, Toe JG et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 144(4), 601-613 (2011).
130. Toe JG, Pellegrini M, Mak TW. Promoting immunity during chronic infection-the therapeutic potential of common gamma-chain cytokines. Mol. Immunol. 56(1-2), 38-47 (2013).
131. Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat. Rev. Immunol. 11(5), 330-342 (2011).
132. Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients (CONVERT). https://clinicaltrials.gov/ct2/show/NCT01027065?term=NCT01027065&rank=1
133. Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients (CONVERT). www.clinicaltrials.gov/ct2/show/NCT01027065
134. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science 324 (5934), 1569-1572 (2009).
135. Frohlich A, Kisielow J, Schmitz I et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324 (5934), 1576-1580 (2009).
136. Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324 (5934), 1572-1576 (2009).
137. Publicover J, Goodsell A, Nishimura S et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J. Clin Invest. 121(3), 1154-1162 (2011).
138. Ma SW, Huang X, Li YY et al. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J. Hepatol. 56(4), 775-781 (2012).
139. Hashmi MH, Van Veldhuizen PJ. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin. Biol. Ther. 10 (5), 807-817 (2010).
140. Boni C, Fisicaro P, Valdatta C et al. Characterization of hepatitis B virus (HBV)-specifc T-cell dysfunction in chronic HBV infection. J. Virol. 81(8), 4215-4225 (2007).
141. Day CL, Kaufmann DE, Kiepiela P et al. PD-1 expression on HIV-specifc T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109), 350-354 (2006).
142. Latchman YE, Liang SC, Wu Y et al. PD-L1-defcient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl Acad. Sci. USA 101(29), 10691-10696 (2004).
143. + T lymphocytes in the liver. J. Immunol. 178(5), 2714-2720 (2007).
144. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27(4), 195-201 (2006).
145. + T cell survival in HIV infection. J. Exp. Med. 203(10), 2281-2292 (2006).
146. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077), 682-687 (2006).
147. Cai G, Karni A, Oliveira EM, Weiner HL, Hafer DA, Freeman GJ. PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell. Immunol. 230(2), 89-98 (2004).
148. Finnefrock AC, Tang A, Li F et al. PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J. Immunol. 182(2), 980-987 (2009).
149. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specifc T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203(10), 2223-2227 (2006).
150. Trautmann L, Janbazian L, Chomont N et al. Upregulation of PD-1 expression on HIV-specifc CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12(10), 1198-1202 (2006).
151. Urbani S, Amadei B, Tola D et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specifc CD8 exhaustion. J. Virol. 80(22), 11398-11403 (2006).
152. Velu V, Titanji K, Zhu B et al. Enhancing SIV-specifc immunity in vivo by PD-1 blockade. Nature 458(7235), 206-210 (2009).
153. Zhang E, Zhang X, Liu J et al. The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection. PLoS ONE 6(10), e26196 (2011).
154. Liu J, Zhang E, Ma Z et al. Enhancing virus-specifc immunity in vivo by combining therapeutic vaccination and pd-l1 blockade in chronic hepadnaviral infection. PLoS Pathog. 10(1), e1003856 (2014).
155. Fisicaro P, Valdatta C, Massari M et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138(2), 682-693, 693 e681-e684 (2010).
156. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
157. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
158. + regulatory T cells correlate with chronic hepatitis B infection. Immunology 123(1), 57-65 (2008).
159. Otano I, Suarez L, Dotor J et al. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B. Hepatology 56(2), 474-483 (2012).
160. Inchauspe G, Michel ML. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J. Viral Hepat. 14(Suppl. 1), 97-103 (2007).
161. Kutscher S, Bauer T, Dembek C, Sprinzl M, Protzer U. Design of therapeutic vaccines: hepatitis B as an example. Microb. Biotechnol. 5(2), 270-282 (2012).
162. Michel ML, Tiollais P. Hepatitis B vaccines: protective effcacy and therapeutic potential. Pathol. Biol. (Paris) 58(4), 288-295 (2010).
163. Bertoletti A, Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev. Gastroenterol. Hepatol. 3(5), 561-569 (2009).
164. Xu DZ, Zhao K, Guo LM et al. A randomized controlled Phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 3(7), e2565 (2008).
165. Yao X, Zheng B, Zhou J et al. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 25(10), 1771-1779 (2007).
166. Xu DZ, Wang XY, Shen XL et al. Results of a Phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and fndings. J. Hepatol. 59(3), 450-456 (2013).
167. Bocher WO, Dekel B, Schwerin W et al. Induction of strong hepatitis B virus (HBV) specifc T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur. J. Immunol. 31(7), 2071-2079 (2001).
168. Lobaina Y, Garcia D, Abreu N, Muzio V, Aguilar JC. Mucosal immunogenicity of the hepatitis B core antigen. Biochem. Biophys. Res. Commun. 300(3), 745-750 (2003).
169. Betancourt AA, Delgado CA, Estevez ZC et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int. J. Infect. Dis. 11(5), 394-401 (2007).
170. Akbar SM, Al-Mahtab M, Uddin MH, Khan MS. HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection. Hepatobiliary Pancreat. Dis. Int. 12(4), 363-369 (2013).
171. Guo Z, Kemmler CB, Mann DL et al. Recombinant yeast therapeutic vaccines expressing hepatitis B virus (HBV) X, S, and core antigens generate antigen specifc T cell responses and tumorprotection in mice. Hepatology 56(4 Suppl.), Abstract 375 (2012).
172. Kemmler CB, Mann DL, King TH et al. Recombinantyeast therapeutic vaccines expressing hepatitis B virus (HBV) X, S, andcore antigens generate antigen specifc T cell responses in clinicalimmune cell samples from healthy volunteers. Hepatology 56(4 Suppl.), Abstract 372 (2012).
173. Martin P, Dubois C, Jacquier E et al. TG1050, a viral-vectorbased immunotherapeutic designed to treat chronic hepatitis B induces immuneresponses with properties similar to those displayed by HBV resolving patientsand has an early antiviral effect in a HBV tolerant model. Hepatology 224A, Abstract 33 (2013).
174. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv. Genet. 55, 25-40 (2005).
175. Scott-Algara D, Mancini-Bourgine M, Fontaine H, Pol S, Michel ML. Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination. PLoS ONE 5(1), e8761 (2010).
176. Yang SH, Lee CG, Park SH et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther. 13 (14), 1110-1117 (2006).
177. Depla E, Van der Aa A, Livingston BD et al. Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J. Virol. 82(1), 435-450 (2008).
178. Pol S, Michel ML. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev. Vaccine 5(5), 707-716 (2006).
179. Senturk H, Tabak F, Ozaras R et al. Effcacy of pre-S-containing HBV vaccine combined with lamivudine in the treatment of chronic HBV infection. Dig. Dis. Sci. 54(9), 2026-2030 (2009).
180. Boni C, Penna A, Bertoletti A et al. Tra nsient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol. 39(4), 595-605 (2003).
181. Boni C, Penna A, Ogg GS et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33(4), 963-971 (2001).
182. Al-Mahtab M, Bazinet M, Vaillant A, Sheikh B. Rep 9AC is a potent HBSAG release inhibitor which clears serum HBSAG and elicits SVRS in patients with chronic hepatitis B. J. Hepatol. 54, S25-S44 (2011).
183. Guo Z, Charles B. Kemmler CB, Mann DL et al. Recombinant yeast therapeutic vaccines expressinghep-atitis B virus (HBV) X, S, and core antigens generate antigen specifc Tcell responses and tumor protection in mice. Hepatology 56(4 Suppl.), 373A-375A (2012).
184. A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults. http://clinicaltrials.gov/show/NCT01779505
185. Safety and Effcacy of GS-4774 for the Treatment of Chronic Hepatitis B. http://clinicaltrials.gov/show/NCT01943799